Study #2025-0059
Quantitative immunofluorescence and/or RT-qPCR for measuring HER2 in HER2-low metastatic breast cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Diagnostic Test: CE-10-IVD
Description
This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
HER2-positive Metastatic Breast Cancer
Study phase:
Physician name:
Jason Mouabbi
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.